Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Verzenio (abemaciclib) tablets Right
  4. Has VERZENIO® (abemaciclib) been studied in head to head clinical trials with other CDK 4 & 6 inhibitors?
Search Verzenio (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Verzenio ® (abemaciclib) tablets

50mg, 100mg, 150mg, 200mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Has VERZENIO® (abemaciclib) been studied in head to head clinical trials with other CDK 4 & 6 inhibitors?

Verzenio (abemaciclib) has not been studied in head to head clinical trials with other CDK4 & 6 inhibitors.

US_cFAQ_ABE031_MOA_OTHER_CDK 4_6_INHIBITORS
US_cFAQ_ABE031_MOA_OTHER_CDK 4_6_INHIBITORS
en-US

Has VERZENIO® (abemaciclib) been studied in head to head clinical trials with other CDK 4 & 6 inhibitors?

Indication

Abemaciclib is indicated

  • in combination with endocrine therapy (ET) (tamoxifen or an aromatase inhibitor [AI]) for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer at high risk of recurrence,
  • in combination with an AI as initial endocrine-based therapy for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer (MBC),
  • in combination with fulvestrant for the treatment of adult patients with HR+, HER2- advanced or MBC with disease progression following ET, and
  • as monotherapy for the treatment of adult patients with HR+, HER2- advanced or MBC with disease progression following ET and prior chemotherapy in the metastatic setting.1

Mechanism of Action Other CDK 4 and 6 Inhibitors

Abemaciclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and CDK6. These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.1

Abemaciclib has not been studied in head-to-head clinical trials with other CDK 4 & 6 inhibitors.

For information on other CDK 4 and 6 inhibitors in this class, please contact the individual manufacturers of these drugs.

Enclosed Prescribing Information

VERZENIO® (abemaciclib) tablets, for oral use, Lilly

Reference

1Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.

Date of Last Review: February 20, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly